Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cytarabine].

K Ota1

  • 1Aichi Cancer Center, Nagoya, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|October 1, 1987
PubMed
Summary
This summary is machine-generated.

Cytarabine (ara-C) effectively treats acute myelogenous leukemia and GI tract cancers. Derivative compounds like BH-AC offer advanced treatment options for acute myelogenous leukemia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Experimental and clinical studies on dysregulation of magnesium metabolism and the aetiopathogenesis of multiple sclerosis.

Magnesium research·1992
Same author

Mechanism of proteinuria in nephrotic syndrome.

Acta medica Okayama·1992
Same author

Effects of nicergoline on calcium and magnesium deposition in the central nervous system tissues of rats maintained on low-calcium diets.

The Journal of international medical research·1992
Same author

Alpha 2-adrenergic receptors are involved in the suppression of luteinizing hormone release during acute fasting in the ovariectomized estradiol-primed rats.

Neuroendocrinology·1992
Same author

[Anti-emetic effect and safety of single dose of ondansetron injection in double-blind comparison study with placebo].

Gan to kagaku ryoho. Cancer & chemotherapy·1992
Same author

[Anti-emetic effect and safety of ondansetron tablet in double-blind comparison with placebo].

Gan to kagaku ryoho. Cancer & chemotherapy·1992
Same journal

[A Case of Pulmonary Epithelioid Hemangioendothelioma Associated with Multiple Cancers].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Long-Term Survival in Three Cases with Pulmonary Metastases from Colorectal Cancer Given Low-Dose S-1 Under a Regimen Combining a Carbohydrate-Restricted Ketogenic Diet, Metformin, Vitamin D, Eicosapentaenoic Acid, and Other Complementary Therapies].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Preventive Effect of Saline Eye Wash for Eye Symptoms Due to High-Dose and Intermediate-Dose Cytarabine Therapy].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Examination of Factors Affecting the Efficacy of Naldemedine Tosilate Tablets for Opioid-Induced Constipation].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Recent Advances in the Treatment of HER2-Altered Solid Tumors].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[BRAF-Mutant Solid Tumor].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Research

Context:

  • Cytarabine (ara-C) is a primary treatment for acute myelogenous leukemia (AML).
  • Combination therapies, such as MFC (mitomycin C, 5-FU, ara-C), show synergistic effects in GI tract cancers and leukemia models.
  • High-dose ara-C is effective for refractory AML cases and used in remission consolidation with daunorubicin.

Purpose:

  • To review the diverse applications and efficacy of cytarabine (ara-C) and its derivatives in cancer therapy.
  • To highlight the role of standard and high-dose cytarabine in treating acute myelogenous leukemia and other cancers.
  • To introduce novel cytarabine derivatives, such as ancitabine and enocitabine (BH-AC), as promising agents for acute myelogenous leukemia.

Summary:

  • Cytarabine (ara-C) demonstrates significant activity in acute myelogenous leukemia (AML) and is used in combination therapies for GI tract cancers.

Related Experiment Videos

  • High-dose ara-C is valuable for refractory AML and consolidation therapy, while low-dose ara-C can induce differentiation in atypical leukemias.
  • Derivative compounds, notably ancitabine and enocitabine (BH-AC), are developed for AML treatment, with BH-AC being a preferred agent in combination regimens.

    • Impact:

    • Cytarabine remains a cornerstone in AML treatment, with dose optimization and combination strategies enhancing its efficacy.
    • The development of cytarabine derivatives broadens therapeutic options, particularly for patients with refractory or difficult-to-treat leukemias.
    • Research into cytarabine and its analogs continues to advance leukemia and GI cancer management, offering new hope for patients.